NeuroLief, a medical technology company based in Coral Springs, Florida, that develops neuromodulation treatments for mental health conditions, has raised $6 million in funding from BrainsWay Ltd.
The news comes after the FDA approved its Proliv™Rx brain neuromodulation system.
The company plans to use the funds to grow its operations and invest more in research and development.
The investment shows a growing need for effective and accessible treatments for adults whose depression does not improve with antidepressant medicines.
“This investment helps us bring proven brain stimulation therapy to patients who haven’t improved with antidepressants,” said Scott Drees, CEO of NeuroLief. “Proliv™Rx was created to fill an important gap in depression treatment. With FDA approval and early market success, we are now expanding a model that provides reliable, evidence-based care in a way that is easy to access and use in real life.”
Read More:Starcloud Raises $170M in Series A Funding
Millions of adults in the United States have depression and do not get enough relief from antidepressants. Although there are other treatment options, many people can’t access them easily due to clinic visits, infrastructure needs, referral delays, and other challenges.
Proliv™Rx is a brain therapy designed to be used at home, helping solve this problem. Approved by the FDA in December 2025, it is prescribed and monitored by a doctor but used by patients themselves at home. This makes advanced depression treatment more accessible while still keeping proper medical supervision.
“As healthcare moves toward value-based care, it’s becoming more important to treat depression patients quickly and effectively,” said Owen Muir, Chief Medical Officer of NeuroLief. “Proliv™Rx was designed for this, offering doctor-supervised brain therapy at home. It helps doctors reach more patients, reduce delays, and overcome the limits of clinic-based treatment.”
About Neurolief
Founded in 2014 by Amit Dar, NeuroLief is a neuroscience-based company that develops noninvasive treatments for mental health and neurological conditions. The company aims to fill important gaps in care by offering scientifically proven treatments that are easy to use and accessible in real life.
About Proliv™Rx
Proliv™Rx is the first FDA-approved prescription brain therapy for adults with major depressive disorder who do not improve with at least one antidepressant. It is prescribed and monitored by a doctor, but patients can use it at home, making advanced treatment available without needing to visit specialized clinics.
About BrainsWay
BrainsWay Ltd. is a global leader in noninvasive brain stimulation treatments for mental health disorders. It uses its Deep TMS™ technology to improve patient outcomes and quality of life. BrainsWay is the only TMS company with three FDA-cleared uses—treating depression, OCD, and smoking addiction—supported by strong clinical studies. The company continues to expand its research and aims to increase awareness and access to these therapies worldwide.
Read More:Mars Men Raises $27.5M in Series A Funding
